CAS: 93269-35-3; (6S,8S,10R,13S,14S,17R)-17-Hydroxy-17-(2-Hydroxyacetyl)-6,10,13-Trimethyl-6,7,8,10,12,13,14,15,16,17-Decahydro-3H-Cyclopenta[a]Phenanthren-3-One (Fluocortolone Impurity)
- 英文名称(6S,8S,10R,13S,14S,17R)-17-Hydroxy-17-(2-Hydroxyacetyl)-6,10,13-Trimethyl-6,7,8,10,12,13,14,15,16,17-Decahydro-3H-Cyclopenta[a]Phenanthren-3-One (Fluocortolone Impurity)
- 中文名称(6S,8S,10R,13S,14S,17R)-17-羟基-17-(2-羟基乙酰基)-6,10,13-三甲基-6,7,8,10,12,13,14,15,16,17-十氢-3H-环戊并[a]菲-3-酮 (甲泼尼龙杂质)
- CAS编号93269-35-3
- MFCD编号:MFCD28359012
- FDA UNII编号:31G2E0J8OF
- 分子式:C22H28O4分子量:356.46
- 产品CID: 1970952
- 产品分类有机原料→分子砌块→手性化合物→手性砌块
相似化合物
93239-37-3 13209-41-1 13504-15-9物理性质
MSDS等安全信息
上下游产品
2-((6S,10R,13S)-17-hydroxy-6,10,13-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate合成工艺路线路线简述
- 927666-76-0 = 93269-35-3
反应条件:1.1 Reagents: Acetic Acid,Potassium Acetate; Rt -> Reflux1.2 Reagents: Water; 110.5 °C
标题:Method For Preparation Of 9,11-Dehydrogen Substance Methylprednisolone Series
参考文献:China]
93239-37-3 = 93269-35-3
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Tetrahydrofuran,Water
标题:Non-Hormonal Steroid Modulators Of Nf-Kb For Treatment Of Disease
参考文献:World Intellectual Property Organization]
83-43-2 = 93269-35-3
反应条件:1.1 Reagents: Chlorosuccinimide,Sulfur Dioxide Catalysts: 4-(Dimethylamino)Pyridine Solvents: Pyridine; 0 °C; 25 Min,0 °C
标题:Preparing Method And Application Of 9,11-Double Bond Steroidal Compound
参考文献:China]
103924-17-0 = 93269-35-3
反应条件:1.1 Solvents: Tetrahydrofuran; 30 °C
标题:A Method For Synthesizing 6A-Methyl Prednisolone
参考文献:China]
93239-37-3 = 93269-35-3
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Tetrahydrofuran,Water
标题:Preparation Of Non-Hormonal Steroid Modulators Of Nf-Kb For Treatment Of Disease
参考文献:World Intellectual Property Organization]
93239-37-3 = 93269-35-3 [标题:Reaction Conditions
标题:Ester Prodrugs Of Steroids
参考文献:European Patent Organization]
= 93269-35-3 [标题:Reaction Conditions
标题:Preparation Of Non-Hormonal Steroid Modulators Of Nf-Kβ For Treatment Of Diseases
参考文献:United States]
= 93269-35-3 [标题:Reaction Conditions
标题:Non-Hormonal Steroid Modulators Of Nf-Kb For Treatment Of Disease
参考文献:United States]
= 93269-35-3 [标题:Reaction Conditions
标题:Synthesis Of Steroids And Inhibition Of Angiogenesis Involving The Coadministration Of The Steroids With Heparin Or Heparin Fragments
参考文献:United States
📜2-((6S,10R,13S)-17-Hydroxy-6,10,13-Trimethyl-3-Oxo-6,7,8,10,12,13,14,15,16,17-Decahydro-3H-Cyclopenta[a]Phenanthren-17-yl)-2-Oxoethyl Acetate置于potassium Carbonate体系中,用 甲醇,乙酸乙酯 作为反应溶剂,化学反应生成 (6Alpha)-17,21-二羟基-6-甲基孕甾-1,4,9(11)-三烯-3,20-二酮
参考文献:Inhibition Of Angiogenesis Involving The Coadministration Of Steroids
标题:Inhibition Of Angiogenesis Involving The Coadministration Of Steroids
摘要:一种抑制温血动物血管反应生成的方法,包括向该动物施用化合物的抗血管反应生成有效量,该化合物的公式为:##str1## 其中c-1和c-2之间的虚线表示双键的存在或不存在; C-6处的 ~键表示α或β; R1是ch3或-c2H5; R2为h,R3在α位上且为-oh,-o-烷基(c1-C12),-oc(=o)烷基(c1-C12),-oc(=o)芳基,-oc(=o)n(R)2或-oc(=o)or7,其中芳基为呋喃基,噻吩基,吡咯基或吡啶基,其中每个杂环基团可选择地用1个或2个(c1-C4)烷基或芳基取代,或芳基为-(ch2)f-苯基,其中f为0至2且苯环可选择地用1至3个从氯,氟,溴,烷基(c1-C3),烷氧基(c1-C3),硫代烷氧基(c1-C3),Cl3C-,F3C-,-nh2和-nhcoch3中选择的基团取代,其中r为氢,烷基(c1-C4)或苯基,每个r可以相同或不同; R7为上述定义的芳基或烷基(c1-C12); 或者r2为α-Cl且r3为β-Cl; 或者r2和r3在c-9和c-11之间形成氧(-O-)桥接; 或者r2和r3在c-9和c-11之间形成双键; R4为h,Ch3,Cl或f; R5为h,Oh,F,Cl,Br,Ch3,苯基,乙烯基或丙烯基; R6为h或ch3; R9为h,Oh,Ch3,F或= Ch2; R10为h,Oh,Ch3或r10在c-16和c-17之间形成第二个键.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
